Cardura Xl (doxazosin recalls
The FDA has published 3 recalls involving Cardura Xl (doxazosin since 2014. The latest was reported on 24 Jul 2024. Most were for potency & assay. Viatris has the most recalls in this group. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls3since 2014
Last 12 months0reported
Class I00% of total
Ongoing0latest 24 Jul 2024
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 2 67%Class III 1 33%
Why cardura xl (doxazosin is recalled
Companies
By year
All cardura xl (doxazosin recalls, newest first
3 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Cardura XL (doxazosin) extended release tablets 4mg recalled by Viatris | Viatris | Potency & Assay | Nationwide |
| Drug | CLASS II | Cardura XL (doxazosin) extended release tablets 8mg recalled by Viatris | Viatris | Potency & Assay | Nationwide |
| Drug | CLASS III | Cardura XL (doxazosin mesylate extended release tablets, 4 mg recalled | Pfizer | Potency & Assay | Nationwide |
Should you stop taking Cardura Xl (doxazosin?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.